Rezolute, Inc. develops therapies for rare and metabolic diseases, with recent company updates centered on hypoglycemia caused by hyperinsulinism. Its principal news themes include ersodetug, the Phase 3 sunRIZE study in congenital hyperinsulinism, the Phase 3 upLIFT study in tumor hyperinsulinism, and clinical evidence from continuous glucose monitoring, biomarker analyses and expanded access experience.
Rezolute news also covers FDA interactions, presentations at pediatric endocrinology and life sciences meetings, quarterly financial results, business updates and investor conference participation. The company’s updates generally connect clinical-program progress with regulatory engagement, cash resources and development priorities for its hyperinsulinism pipeline.
Rezolute (RZLT) completed enrollment in its Phase 3 upLIFT study of ersodetug for uncontrolled low blood sugar caused by tumor hyperinsulinism. The single-arm, open-label study enrolled 16 participants with insulinoma or non-islet cell tumors. Rezolute expects topline results in mid-December 2026.
The primary endpoint measures participants achieving at least a 50 percent reduction in intravenous glucose infusion rate within the 8-week pivotal treatment phase. Statistical significance requires at least a 56% response rate for 16 participants. Previously reported results showed 7 of the first 8 participants met the endpoint and stopped intravenous glucose completely. The eighth died from cancer progression after choosing hospice care and is counted as a non-responder. No drug-related safety findings have been reported thus far. Rezolute plans to continue compassionate access and potentially advance both tumor and congenital hyperinsulinism indications in 2027 if outcomes are favorable.
Rezolute (RZLT) announced that FDA recommended a pre-BLA meeting before a potential biologics license application for ersodetug in congenital hyperinsulinism.
Following preliminary review of Phase 3 sunRIZE data, FDA encouraged the next regulatory step despite missed primary and key secondary endpoints. Reductions in low-blood-sugar events measured by finger-stick testing were not statistically significant versus placebo. The continuous glucose monitoring endpoint also missed its Week 24 target, although improvements appeared across multiple monitoring-based endpoints in both treatment arms. FDA did not assess approvability; that determination requires formal application review.
Rezolute expects Phase 3 upLIFT results in tumor-related hyperinsulinism this quarter and will then evaluate its submission strategy for potentially both programs. A tumor-related pre-BLA meeting depends on results supporting a submission.
Rezolute (RZLT) reported fiscal 2026 results and updated its ersodetug studies on September 24, 2026.
In its ongoing Phase 3 upLIFT study for tumor-related hyperinsulinism (HI), seven of eight enrolled participants met the primary endpoint's responder criterion. Six also stopped intravenous glucose with ersodetug. The eighth participant withdrew before finishing the pivotal treatment phase and is counted as a non-responder. Enrollment continues; Rezolute expects topline results before the end of 2026. Its Phase 3 sunRIZE study in congenital HI did not meet its primary endpoint, and the data remain under FDA review.
Cash, cash equivalents and marketable securities totaled $107.8 million at June 30, 2026, versus $167.9 million a year earlier. Fiscal 2026 net loss was $77.6 million versus $74.4 million in fiscal 2025. Research and development expense fell to $53.8 million from $61.5 million, while general and administrative expense rose to $29.2 million from $18.4 million.
Rezolute (RZLT) reported that the U.S. FDA is continuing its review of extensive Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism (HI), with no defined timeline for regulatory feedback.
The pivotal sunRIZE trial previously showed reductions from baseline in hypoglycemia events but did not meet its primary or key secondary endpoints versus placebo. At FDA’s request, Rezolute submitted source and analysis datasets, including numerous pre‑specified, post‑hoc and sensitivity analyses focused on continuous glucose monitoring (CGM) outcomes. The company believes these data show consistent glycemic improvements in ersodetug arms, including ≥50% reductions in average daily percent time in hypoglycemia and average weekly hypoglycemia events.
The sunRIZE open‑label extension phase continues with high retention and reduced use of background standard of care therapies. Enrollment also continues in the Phase 3 upLIFT study in tumor HI, with topline results expected before the end of 2026.
Rezolute (RZLT) will participate in three upcoming investor conferences in September 2026, including events hosted by Cantor, H.C. Wainwright, and Morgan Stanley. Management will take part in fireside chats and one-on-one investor meetings during these conferences and invites interested investors to schedule meetings through the respective bank representatives.
Rezolute (Nasdaq:RZLT) announced that its management team will participate in the BTIG Virtual Biotechnology Conference, held on July 28-29, 2026. Management will conduct one-on-one investor meetings, which can be scheduled through BTIG representatives. Rezolute focuses on treating refractory hypoglycemia from congenital or acquired hyperinsulinism and is developing the antibody therapy ersodetug, studied in clinical trials and real-world HI cases.
Rezolute (Nasdaq:RZLT) reported four presentations at the Endocrine Society’s annual ENDO meeting covering congenital and tumor hyperinsulinism (HI). Two posters detailed systematic natural history and health‑economic outcomes in congenital HI. Another poster showed Expanded Access Program tumor HI data, and an oral session reviewed Phase 3 sunRIZE congenital HI results.
In 9 tumor HI patients with refractory hypoglycemia, 75% on IV dextrose/TPN achieved complete discontinuation. Rezolute views these data, alongside natural history analyses, as supporting development and potential future launch of ersodetug for congenital and tumor HI.
Rezolute (Nasdaq:RZLT) will deliver four presentations at the Endocrine Society’s ENDO 2026 meeting in Chicago from June 13-16, 2026.
The schedule includes an oral presentation of Phase 3 sunRIZE top-line results for congenital hyperinsulinism and three posters covering congenital and tumor hyperinsulinism outcomes and ersodetug (RZ358) clinical experience.
Rezolute (Nasdaq:RZLT) reported positive interim data from its open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. The trial is 50% enrolled, with 8 of 16 planned participants.
According to Rezolute, 6 of 8 participants met the primary endpoint responder criterion and fully discontinued intravenous glucose. Ersodetug has been well-tolerated with no drug-related adverse events reported. Topline results are expected in the second half of 2026.
Rezolute (Nasdaq:RZLT) reported fiscal Q3 2026 results and clinical updates for ersodetug in hyperinsulinism.
Expanded Phase 3 sunRIZE analyses in congenital HI showed CGM-based reductions in hypoglycemia and increased normoglycemia exposure versus placebo. FDA held a Type B meeting and encouraged submission of comprehensive datasets. Tumor HI Phase 3 upLIFT enrollment continues, with topline data expected in 2H 2026.
Cash and investments were $120.3M at March 31, 2026, versus $167.9M at June 30, 2025. Q3 R&D was $11.4M, G&A $6.0M, and net loss $16.2M, all improving or increasing versus the prior-year quarter as specified.